{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T02:45:32Z","timestamp":1768877132197,"version":"3.49.0"},"reference-count":24,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.3892\/ol.2015.2954","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T08:21:11Z","timestamp":1423556471000},"page":"1822-1826","source":"Crossref","is-referenced-by-count":15,"title":["Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancer"],"prefix":"10.3892","volume":"9","author":[{"given":"SEIKI","family":"TAKASHIMA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SACHIKO","family":"KIYOTO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MINA","family":"TAKAHASHI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"FUMIKATA","family":"HARA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"KENJIRO","family":"AOGI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SHOZO","family":"OHSUMI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RYOKO","family":"MUKAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YORIKO","family":"FUJITA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2015,2,10]]},"reference":[{"key":"key20180108102854_b1-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b2-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1200\/JCO.1990.8.7.1263","article-title":"Hypersensitivity reactions from taxol","volume":"8","author":"Weiss","year":"1990","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b3-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ejca.2005.06.030","article-title":"Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes","volume":"42","author":"Mielke","year":"2006","journal-title":"Eur J Cancer"},{"key":"key20180108102854_b4-ol-09-04-1822","volume-title":"Taxol\u00ae (paclitaxel) injection [packaging insert]","year":"2007"},{"key":"key20180108102854_b5-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b6-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"key20180108102854_b7-ol-09-04-1822","unstructured":"Japan Clinical Oncology GroupCommon Terminology Criteria for Adverse Events version 4.0http:\/\/www.jcog.jp\/doctor\/tool\/CTCAEv4J_20140920.pdfAccessed December 10, 2014"},{"key":"key20180108102854_b8-ol-09-04-1822","volume-title":"Abraxane\u00ae for Injectable Suspension (nab-paclitaxel) [packaging insert]","year":"2013"},{"key":"key20180108102854_b9-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1200\/JCO.1996.14.6.1858","article-title":"Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer","volume":"14","author":"Nabholtz","year":"1996","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b10-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","article-title":"Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer","volume":"23","author":"Jones","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b11-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1200\/JCO.2007.11.9362","article-title":"Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b12-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"R66","DOI":"10.1186\/bcr1622","article-title":"Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342","volume":"8","author":"Harris","year":"2006","journal-title":"Breast Cancer Res"},{"key":"key20180108102854_b13-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (Taxol)","volume":"332","author":"Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"key20180108102854_b14-ol-09-04-1822","first-page":"455","article-title":"Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management","volume":"6","author":"Swain","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"key20180108102854_b15-ol-09-04-1822","first-page":"209","article-title":"Nanoparticle paclitaxel (ABI-007) in metastatic breast cancer (MBC): efficacy and evidence of dose-dependent activity in two multicenter phase II studies","volume":"21","author":"Ibrahim","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"key20180108102854_b16-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00520-005-0782-y","article-title":"Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin\/paclitaxel-based chemotherapy - a double-blind, placebo-controlled randomized phase II study from the Arbeitsgemeinschaft Gyn\u00e4kologische Onkologie (AGO) Ovarian Cancer Study Group","volume":"13","author":"Hilpert","year":"2005","journal-title":"Support Care Cancer"},{"key":"key20180108102854_b17-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ygyno.2004.11.052","article-title":"A randomized phase II study of paclitaxel with carboplatin +\/\u2212 amifostine as first line treatment in advanced ovarian carcinoma","volume":"97","author":"De Vos","year":"2005","journal-title":"Gynecol Oncol"},{"key":"key20180108102854_b18-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdg301","article-title":"Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients","volume":"14","author":"Lorusso","year":"2003","journal-title":"Ann Oncol"},{"issue":"July 15 Suppl","key":"key20180108102854_b19-ol-09-04-1822","first-page":"5021","article-title":"Cytoprotection of amifostine (A) in ovarian cancer patients receiving paclitaxel\/carboplatin (PC) first line chemotherapy in a multicenter phase III trial","volume":"22","author":"Sevelda","year":"2004","journal-title":"J Clin Oncol, 2004 ASCO Annual Meeting Proc (Post-Meeting Edition)"},{"key":"key20180108102854_b20-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2003.11.005","article-title":"Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer","volume":"21","author":"Leong","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b21-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.1999.17.10.3038","article-title":"Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer","volume":"17","author":"Gelmon","year":"1999","journal-title":"J Clin Oncol"},{"key":"key20180108102854_b22-ol-09-04-1822","first-page":"274","article-title":"Glutamine does not prevent paclitaxel-associated myalgias and arthralgias","volume":"1","author":"Jacobson","year":"2003","journal-title":"J Support Oncol"},{"key":"key20180108102854_b23-ol-09-04-1822","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1212\/01.WNL.0000148609.35718.7D","article-title":"Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial","volume":"64","author":"Argyriou","year":"2005","journal-title":"Neurology"},{"key":"key20180108102854_b24-ol-09-04-1822","unstructured":"Center for Cancer Control and Information ServicesNational Estimates of Cancer Incidence Based on Cancer Registries in Japan (1975\u20132010)http:\/\/ganjoho.jp\/pro\/statistics\/en\/table_download.html#02Accessed December 10, 2014"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2015.2954\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T08:23:30Z","timestamp":1515399810000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2015.2954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,10]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,2,10]]},"published-print":{"date-parts":[[2015,4]]}},"alternative-id":["10.3892\/ol.2015.2954"],"URL":"https:\/\/doi.org\/10.3892\/ol.2015.2954","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,10]]}}}